Trial Search Results

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-02341066

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - histologically or cytologically proven diagnosis of non-small cell lung cancer

   - positive for the ALK fusion gene (test provided by either a central laboratory. Local
   laboratory may be used for certain cases)

   - may have received pemetrexed or docetaxel from previous Phase 3 trial (A8081007) and
   discontinued treatment due to Response Evaluation Criterion in Solid Tumors
   (RECIST)-defined progression. or, once the primary endpoint of Study A8081007 has been
   analyzed and the results made available, at any time without RECIST-defined
   progression.

   - Tumors can be measurable or non measurable

Exclusion Criteria:

   - prior treatment with PF-02341066

   - received no prior systemic treatment, chemotherapy or EGFR tyrosine kinase inhibitor,
   for advanced non-small cell lung cancer

   - current enrollment in another therapeutic clinical trial

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting